投资人过去三年投资创新药真的非常爽 | 海斌访谈

Core Insights - The biopharmaceutical sector in China is experiencing a recovery, with significant growth in stock performance, particularly in Hong Kong listings [1] - The Hang Seng Biotech Index has risen by 80% this year, indicating a positive trend in the industry [1] - Notable companies like BeiGene have reached a three-year high in market capitalization, reflecting renewed investor confidence [1] Industry Summary - The biopharmaceutical industry and investors have emerged from a challenging period, suggesting that the downturn may have presented the best investment opportunities [1] - Investment in innovative drugs over the past three years has been highly rewarding, with significant valuation adjustments and opportunities for engagement with industry leaders [1]